Updated:
BioIntelliSense
BioIntelliSense is a continuous health monitoring and clinical intelligence company. The BioButton system delivers scalable continuous monitoring that...
Overview
BioIntelliSense is a continuous health monitoring and clinical intelligence company. The BioButton system delivers scalable continuous monitoring that proactively identifies early signs of patient deterioration. Its wearable continuous monitoring solution collects and analyzes leading indicators of patient decline for in-facility and home use, with BioDashboard exception management software.
General information
Firm type
other
Location
Region
North America
Country
United States
City
Golden
Corporate office
Golden, CO, United States
Sector focus
Frequently asked questions
Who leads BioIntelliSense?
BioIntelliSense does not publicly name its CEO or executive team. The company's website and public filings list no individuals in leadership roles. This contrasts with many health-tech firms that highlight founder or executive backgrounds.
How does BioIntelliSense generate revenue?
BioIntelliSense sells or licenses the BioButton system—hardware, software, and monitoring service—to hospitals, health systems, and post-acute care organizations. The company does not offer direct-to-consumer sales, per its website.
Does BioIntelliSense have venture capital or other institutional investors?
BioIntelliSense has not disclosed any institutional investors, venture capital rounds, or debt financing. Its ownership structure is unknown. This opacity is unusual for a company marketing clinical-trial-level outcomes.
What published evidence supports BioIntelliSense's clinical claims?
BioIntelliSense's website cites several peer-reviewed studies, including research from Houston Methodist published in the Journal of Clinical Medicine (Weller et al., 2024) and a before-and-after study in the British Journal of Anaesthesia (Eddahchouri et al., 2022). The company also references internal analyses from American Health Network and Houston Methodist Hospital.
How does BioIntelliSense's solution differ from standard telemetry or spot-check monitoring?
BioIntelliSense claims that continuous monitoring via the BioButton, compared to intermittent manual vital checks, reduces ICU transfers, rapid response activations, and hospital stays (per studies cited by the company). The system also transitions from in-hospital to home use, a feature not common with traditional telemetry.
Profile maintained by Altss. Updated: . To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: